Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment

Journal of Clinical Investigation

Volumn 105, Issue 4, 2000, Pages 451-458

  Knowles, Joshua W ^a,b   Reddick, Robert L ^c   Jennette, J Charles ^a   Shesely, Edward G ^a,d   Smithies, Oliver ^a,b   Maeda, Nobuyo ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; ENALAPRIL; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; DISEASE ASSOCIATION; ENZYME DEFICIENCY; HYPERTENSION; KIDNEY DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 0034004826     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8376     Document Type: Article

References (53)

1. World Health Organization. 1998. The world health report. 1998. World Health Organization. Geneva, Switzerland. 125-126.
2. Braunwald, E. 1997. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N. Engl. J. Med. 337:1360-1369.
3. Chobanian, A.V., and Alexander, R.W. 1996. Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch. Intern. Med. 156:1952-1956.
4. Doyle, A.E. 1990. Does hypertension predispose to coronary artery disease? In Hypertension: pathophysiology, diagnosis and management. J.H. Laragh and B.M. Brenner, editors. Raven Press Ltd. New York, NY. 119-125.
5. SHEP Cooperative Research Group. 1991. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 265:3255-3264.
6. Collins, R., et al. 1990. Blood pressure, stroke, and coronary heart disease. II. Short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 335:827-838.
7. Moncada, S., and Higgs, A. 1993. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329:2002-2012.
8. Shesely, E.G., et al. 1996. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA. 93:13176-13181.
9. Huang, P.L., et al. 1995. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 377:239-242.
10. Bonnardeaux, A., et al. 1995. Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension. Circulation. 91:96-102.
11. Loscalzo, J., and Welch, G. 1995. Nitric oxide and its role in the cardiovascular system. Prog. Cardiovasc. Dis. 38:87-104.
12. Cox, D.A., et al. 1989. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 80:458-465.
13. Mahley, R.W. 1988. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 240:622-630.
14. Krege, J.H., Hodgin, J.B., Hagaman, J.R., and Smithies, O. 1995. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25:1111-1115.
15. Zhang, S.H., Reddick, R.L., Piedrahita, J.A., and Maeda, N. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468-471.
16. Laubach, V.E., Shesely, E.G., Smithies, O., and Sherman, P.A. 1995. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc. Natl. Acad. Sci USA. 92:10688-10692.
17. Zhang, S.H., Reddick, R.L., Burkey, B., and Maeda, N. 1994. Diet-induced atherosclerosis in mice heterozygous and homoxygous for apolipoprotein E gene disruption. J Clin. Invest. 94:937-945.
18. Kim, J.G., et al. 1997. Generation of a polyclonal antibody against lipid peroxide-modified proteins. Free Radic. Biol. Med. 23:251-259.
19. Alexander, R.W. 1995. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 25:155-161.
20. Esaki, T., et al. 1997. Expression of inducible nitric oxide synthase in T lymphocytes and macrophages of cholesterol-fed rabbits. Atherosclerosis. 128:39-46.
21. MacMicking, J.D., et al. 1995. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase [erratum 1995, 81:1170]. Cell. 81:641-650.
22. Sugiyama, F., et al. 1997. Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system. Lab. Invest. 76:835-842.
23. Makaritsis, K.P., Gavras, H., Du, Y., Chobanian, A.V., and Brecher, P. 1998. Alpha 1-adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice. Hypertension. 32:1044-1048.
24. Gimbrone, M.A., Jr. 1999. Vascular endothelium, hemodynamic forces, and atherogenesis. Am. J. Pathol. 155:1-5.
25. Thubrikar, M.J., and Robicsek, F. 1995. Pressure-induced arterial wall stress and atherosclerosis. Ann. Thorac. Surg. 59:1594-1603.
26. Zand, T., et al. 1999. Lipid deposition in rat aortas with intraluminal hemispherical plug stenosis. A morphological and biophysical study. Am. J. Pathol. 155:85-92.
27. Giddens, D.P., Zarins, C.K., and Glagov, S. 1993. The role of fluid mechanics in the localization and detection of atherosclerosis. J. Biomech. Eng. 115:588-594.
28. Meyer, G., Merval, R., and Tedgui, A. 1996. Effects of pressure-induced stretch and convection on low-density lipoprotein and albumin uptake in the rabbit aortic wall. Circ. Res. 79:532-540.
29. Rudic, R.D., et al. 1998. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J. Clin. Invest. 101:731-736.
30. Hayek, T., Attias, J., Smith, J., Breslow, J.L., and Keidar, S. 1998. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. 31:540-544.
31. Keidar, S., Attias, J., Smith, J., Breslow, J.L., and Hayek, T. 1997. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem. Biophys. Res. Commun. 236:622-625.
32. Benzie, I.F., and Tornlinson, B. 1998. Antioxidant power of angiotensin-converting enzyme inhibitors in vitro. Br. J. Clin. Pharmacol. 45:168-169.
33. Mancini, G.B., et al. 1996. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) [erratum 1996, 94:1490]. Circulation. 94:258-265.
34. Dzau, V.J. 1998. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur. Heart J. 19(Suppl.):J2-J6.
35. Chobanian, A.V., Haudenschild, C.C., Nickerson, C., and Drago, R. 1990. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 15:327-331.
36. Kowala, M.C., Grove, R.I., and Aberg, G. 1994. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis. 108:61-72.
37. Gibbons, G.H. 1997. Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition: the homeostatic balance between angiotensin II and nitric oxide. Clin. Cardiol. 20(Suppl. 2):II18-25.
38. Chobanian, A.V., Brecher, P., and Chan, C. 1985. Effects of propranolol on atherogenesis in the cholesterol-fed rabbit. Circ. Res. 56:755-762.
39. Kaplan, J.R., Manuck, S.B., Adams, M.R., Weingand, K.W., and Clarkson, T.B. 1987. Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation. 76:1364-1372.
40. Henry, P.D., and Bentley, K.I. 1981. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J. Clin. Invest. 68:1366-1369.
41. Elhage, R., et al. 1997. Prevention of fatty streak formation of 17beta-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice. Circulation. 96:3048-3052.
42. Behr, D., Rupin, A., Fabiani, J.N., and Verbeuren, T.J. 1999. Distribution and prevalence of inducible nitric oxide synthase in atherosclerotic vessels of long-term cholesterol-fed rabbits. Atherosclerosis. 142:335-344.
43. Manttari, M., Tiula, E., Alikoski, T., and Manninen, V. 1995. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 26:670-675.
44. Baylis, C., Mitruka, B., and Deng, A. 1992. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J. Clin. Invest. 90:278-281.
45. Ribeiro, M.O., Antunes, E., Muscara, M.N., De Nucci, G., and Zatz, R. 1995. Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertension. 26:150-155.
46. Ribeiro, M.O., Antunes, E., de Nucci, G., Lovisolo, S.M., and Zatz, R. 1992. Chronic inhibition of nitric oxide synthesis. A new model of arterial hypertension. Hypertension. 20:298-303.
47. Moorhead, J.F., Chan, M.K., El-Nahas, M., and Varghese, Z. 1982. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 2:1309-1311.
48. Magil, A.B. 1999. Interstitial foam cells and oxidized lipoprotein in human glomerular disease. Mod. Pathol. 12:33-40.
49. Amatruda, J.M., Margolis, S., and Hutchins, G.M. 1974. Type 3 hyperlipoproteinemia with mesangial foam cells in renal glomeruli. Arch. Pathol. Lab. Med. 98:51-54.
50. Meyrier, A., Hill, G.S., and Simon, P. 1998. Ischemic renal diseases: new insights into old entities. Kidney Int. 54:2-13.
51. Hollenberg, N.K., and Raij, L. 1993. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch. Intern. Med. 153:2426-2435.
52. Maschio, G., et al. 1999. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J. Cardiovasc. Pharmacol. 33(Suppl. 1):S16-S20; discussion S41-43.
53. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 362:801-809.